ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Initial Experience with Donor Specific Tregs in Kidney Transplantation.

J. Markmann,1 E. Guinan,2 E. Geissler,3 G. Cole,2 S. Germana,1 J. Kim,1 B. Sawitzki.4

1Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
2Hematology/Oncology, Dana-Farber Cancer Center, Boston, MA
3Surgery, Universitätsklinikum Regensburg, Regensburg, Germany
4Institute of Medical Immunology, Charite Universitätsmedizin, Berlin, Germany.

Meeting: 2016 American Transplant Congress

Abstract number: 191

Keywords: Kidney transplantation, T cells, Tolerance

Session Information

Session Name: Concurrent Session: Clinical Science: Tolerance: Clinical Studies

Session Type: Concurrent Session

Date: Monday, June 13, 2016

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:54pm-4:06pm

Location: Room 304

Systematic multicenter clinical evaluation of regulatory cells is being conducted by the EU supported ONE Study trial in which each site is administering a different regulatory population (non- donor specific Tregs, donor specific Tregs (dsTregs), reg-marophages, and tol-DCs) using a common immunosuppressive protocol. We report the first clinical application of dsTregs to kidney recipients as part of the ONE Study.

dsTregs were generated (Guinan et al, STM 2009)by culturing donor and recipient PBL in MLRs with addition of costimulatory blockade (bela). We documented feasibility in vitro with ESRD patient cells finding a similar 2-3X expansion of Tregs after MLR+belatacept. dsTregs isolated post 3 d culture under GMP were purified by sequential negative (CD19, CD8) and positive (CD25) magnetic bead selection for CD4+CD25+ to >95% Foxp3+, and we found these cells had >95% TSDR demethylation. Antigen specificity was verified by suppression of donor but not third party responses and a phase I trial of dsTregs in live donor renal transplants initiated (NCT0209123).

Two patients enrolled were males age 47 (GN) and 53 (IgA) transplanted with LURDs. Frozen donor and recipient PBMCs were processed 1 wk post-op. 3 d later recipients received dsTregs at ~ 2×10(4)/kg. No complications accompanied the infusion. Both successfully discontinued steroids at 15 weeks. At 5 and 8 mo post-tx, both have excellent graft function. Protocol bx at 9 mo will determine eligibility to discontinue MMF leaving only low-dose maintenance tacro. Patient 2 initially experienced mild DGF prior to receiving dsTregs and a slight rise in the creat. on d 12 prompted bx which revealed no rejection. A mild T cell infiltrate was present that was rich in Foxp3+ CD4.

We initiated the first human organ transplant trial of purified dsTregs and demonstrated the feasibility and preliminary safety of dsTreg therapy. While numbers and follow up are limited, there have been no adverse events suggesting safety. In subsequent patients, the dose of Tregs will be escalated. We expect these preliminary studies to lay the foundation for addition of cell based dsTregs to the armamentarium of therapies to prevent rejection and promote transplant tolerance.

CITATION INFORMATION: Markmann J, Guinan E, Geissler E, Cole G, Germana S, Kim J, Sawitzki B. Initial Experience with Donor Specific Tregs in Kidney Transplantation. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Markmann J, Guinan E, Geissler E, Cole G, Germana S, Kim J, Sawitzki B. Initial Experience with Donor Specific Tregs in Kidney Transplantation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/initial-experience-with-donor-specific-tregs-in-kidney-transplantation/. Accessed May 8, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences